USRE39308E1 - 3,5-dioxa-12-azawurtzitane compound and process of preparing same - Google Patents
3,5-dioxa-12-azawurtzitane compound and process of preparing same Download PDFInfo
- Publication number
- USRE39308E1 USRE39308E1 US10/840,740 US84074004A USRE39308E US RE39308 E1 USRE39308 E1 US RE39308E1 US 84074004 A US84074004 A US 84074004A US RE39308 E USRE39308 E US RE39308E
- Authority
- US
- United States
- Prior art keywords
- group
- dioxa
- azawurtzitane
- polypeptide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 20
- 229920001184 polypeptide Polymers 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 14
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- -1 benzoxycarbonyl Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229920001308 poly(aminoacid) Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 28
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 0 *N1C2OC3(C)OC1C1(C)CC2(C)CC3(C)C1.*N1C2OC3(C)OC1C1(C)CC2(C)CC3(C)C1 Chemical compound *N1C2OC3(C)OC1C1(C)CC2(C)CC3(C)C1.*N1C2OC3(C)OC1C1(C)CC2(C)CC3(C)C1 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- KOWUZXVJOUDTRD-UHFFFAOYSA-N C.C.CC1=CNC2C=CC=CC12.CCC1=CN=CN1 Chemical compound C.C.CC1=CNC2C=CC=CC12.CCC1=CN=CN1 KOWUZXVJOUDTRD-UHFFFAOYSA-N 0.000 description 1
- IAAREFBMTUIBPU-UHFFFAOYSA-N C.C.CCC1=CN=CN1.CCC1=CNC2=C1C=CC=C2 Chemical compound C.C.CCC1=CN=CN1.CCC1=CNC2=C1C=CC=C2 IAAREFBMTUIBPU-UHFFFAOYSA-N 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N CC1=CC=C(O)C=C1 Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N CC1=CC=CC=C1 Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N CC1=CN=CN1 Chemical compound CC1=CN=CN1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- PPYXRCRJNNSOSQ-RQOWECAXSA-N CS(=S)C/C=C(/N)OO Chemical compound CS(=S)C/C=C(/N)OO PPYXRCRJNNSOSQ-RQOWECAXSA-N 0.000 description 1
- YIWFXZNIBQBFHR-LURJTMIESA-N Gly-His Chemical group [NH3+]CC(=O)N[C@H](C([O-])=O)CC1=CN=CN1 YIWFXZNIBQBFHR-LURJTMIESA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N [H]N1C=C(C)C2=C1C=CC=C2 Chemical compound [H]N1C=C(C)C2=C1C=CC=C2 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010009297 diglycyl-histidine Proteins 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Definitions
- This invention relates to a 3,5-dioxa-12-azawurtzitane compound and a process of preparing same.
- the new class of dioxa-azawurtzitane compounds of the present invention have a structure similar to an amino acid or a polypeptide and will be utilizable for various applications, for example, as a molecular recognition agent for use in neurotransmission studies, an intermediate for a protein-resembling compound, a surfactant, a protective group and a host-guest complex for use as a sensor.
- a dioxa-azawurtzitane of the following formula is reported by Hiroshi IZUMI and Shigeru FUTAMURA in J. Chem. Soc., Perkin Trans. 1, 1925 (1998): in which Me stands for a methyl group and R stands for a 4-methoxybenzyl group, a 2-(pyridin-2-yl)ethyl group or a 2-(imidazol-4-yl)ethyl group.
- the known wurtzitane compounds do not have a structure similar to an amino acid or a polypeptide.
- a 3,5-dioxa-12-azawurtzitane compound represented by the following formula (I): wherein R 1 represents an alkyl group, R 2 represents a group which, together with a —CH(NH 2 )COOH group, constitutes an ⁇ -amino acid of the formula R 2 CH(NH 2 )COOH and which may contain one or more substituents and R 3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a polyamino acid.
- R 1 represents an alkyl group
- R 2 represents a group which, together with a —CH(NH 2 )COOH group, constitutes an ⁇ -amino acid of the formula R 2 CH(NH 2 )COOH and which may contain one or more substituents
- R 3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a
- the present invention provides a process of preparing a 3,5-dioxa-12-azawurtzitane compound represented by the following formula (I): wherein R 1 represents an alkyl group, R 2 represents a group which, together with a —CH(NH 2 )COOH group, constitutes an ⁇ -amino acid of the formula R 2 CH(NH 2 )COOH and which may contain one or more substituents and R 3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a polyamino acid, said process comprising reacting an amino acid, an oligo- or polypeptide or a polyamino acid with a trialdehyde represented by the following formula (II): wherein R 1 has the same meaning as above.
- R 1 represents an alkyl group
- R 2 represents a group which, together with a —CH(NH 2 )COOH group, constitutes an ⁇ -amino
- the three R 1 s bonded to the carbon atoms at 1-, 7- and 9-positions of the 3,5-dioxa-12-azawurtzitane compound of the formula (I) or at 1-, 3- and 5-positions of the trialdehyde of the formula (II) may be the same or different alkyl groups.
- R 1 represents an alkyl group preferably having 1-12 carbon atoms.
- suitable alkyl groups of R 1 are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and structural isomers thereof.
- R 2 represents a group which, together with a —CH(NH 2 )COOH group, constitutes an ⁇ -amino acid of the formula R 2 CH(NH 2 )COOH.
- ⁇ -amino acids R 2 CH(NH 2 )COOH include glycine (Gly), alanine (Ala), Valine (Val), leucine (Leu), Isoleucine (Ileua), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Try), serine (Ser), threonine (Thre), cystein (CySH), cystine (CyS-SCy), methionine (Meth), aspartic acid (Asp), glutamic acid (Glu), lysine (Lys), arginine (Arg) and histidine (His).
- the group R 2 may contain one or more substituents such as an alkyl group, an acetyl group, an alkoxy group, a benzoxycarbonyl group, a tert-butoxycarbonyl group, a 9-fluorenylmethoxycarbonyl group and a 1,7,9-trialkyl-3,5-dioxa-12H-azawurtzitan-12-yl group.
- substituents such as an alkyl group, an acetyl group, an alkoxy group, a benzoxycarbonyl group, a tert-butoxycarbonyl group, a 9-fluorenylmethoxycarbonyl group and a 1,7,9-trialkyl-3,5-dioxa-12H-azawurtzitan-12-yl group.
- R 3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a polyamino acid.
- n is an integer.
- the 3,5-dioxa-12-azawurtzitane compounds of the formula (I) may be prepared by reacting a trialdehyde of the formula (II) with an amino acid, an oligo- or polypeptide or a polyamino acid.
- the reaction is as follows:
- the trialdehyde of the formula (II) may be obtained by any known method such as a method described in Hiroshi IZUMI and Shigeru FUTAMURA, J. Org. Chem. vol. 64, 4502 (1999), the disclosure of which is hereby incorporated by reference herein.
- the raw material to be reacted with the trialdehyde of the formula (II) may be expressed by the following formula (III): (Z) n (III) wherein Z represents an amino acid and n is an integer of 1 or more with the proviso that, when n is two or more, the amino acids may be the same or different.
- Any amino acid may be used as Z of the formula (III).
- amino acids include glycine (Gly), alanine (Ala), Valine (Val), leucine (Leu), Isoleucine (Ileu), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Try), serine (Ser), threonine (Thre), cystein (CySH), cystine (CyS-SCy), methionine (Meth), aspartic acid (Asp), glutamic acid (Glu), lysine (Lys), arginine (Arg) and histidine (His).
- Any oligopeptide (composed of 2 to 9 amino acids), polypeptide (composed of 10 or more amino acids) or polyamino acid (composed of two or more amino acids) may be used as a raw material for the above reaction.
- the reaction may be performed by mixing an aqueous solution of an amino acid, an oligo- or polypeptide or a polyamino acid with an organic polar solvent solution of the trialdehyde of the formula (II), and reacting the resulting mixture at a temperature and for a period of time sufficient to produce the desired 3,5-dioxa-12-azawurtzitane compound.
- the trialdehyde is generally used in a stoichiometric amount.
- the aqueous solution may be a buffer solution.
- the organic polar solvent may be an aprotic one compatible with water, such as acetone or acetonitrile.
- the reaction is preferably carried out at 0-70° C. for 0.5-24 hours.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
A 3,5-dioxa-12-azawurtzitane compound represented by the formula (I) shown in the specification. The dioxaazawurtzitane compound may be prepared by reacting an amino acid, an oligo- or polypeptide or a polyamino acid with a trialdehyde represented by formula (II) shown in the specification.
Description
This invention relates to a 3,5-dioxa-12-azawurtzitane compound and a process of preparing same. The new class of dioxa-azawurtzitane compounds of the present invention have a structure similar to an amino acid or a polypeptide and will be utilizable for various applications, for example, as a molecular recognition agent for use in neurotransmission studies, an intermediate for a protein-resembling compound, a surfactant, a protective group and a host-guest complex for use as a sensor.
A dioxa-azawurtzitane of the following formula is reported by Hiroshi IZUMI and Shigeru FUTAMURA in J. Chem. Soc., Perkin Trans. 1, 1925 (1998):
in which Me stands for a methyl group and R stands for a 4-methoxybenzyl group, a 2-(pyridin-2-yl)ethyl group or a 2-(imidazol-4-yl)ethyl group. The known wurtzitane compounds do not have a structure similar to an amino acid or a polypeptide.
in which Me stands for a methyl group and R stands for a 4-methoxybenzyl group, a 2-(pyridin-2-yl)ethyl group or a 2-(imidazol-4-yl)ethyl group. The known wurtzitane compounds do not have a structure similar to an amino acid or a polypeptide.
It is an object of the present invention to provide a 3,5-dioxa-12-azawurtzitane compound having a structure similar to an amino acid or a polypeptide.
In accordance with one aspect of the present invention, there is provided a 3,5-dioxa-12-azawurtzitane compound represented by the following formula (I):
wherein R1 represents an alkyl group, R2 represents a group which, together with a —CH(NH2)COOH group, constitutes an α-amino acid of the formula R2CH(NH2)COOH and which may contain one or more substituents and R3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a polyamino acid.
wherein R1 represents an alkyl group, R2 represents a group which, together with a —CH(NH2)COOH group, constitutes an α-amino acid of the formula R2CH(NH2)COOH and which may contain one or more substituents and R3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a polyamino acid.
In another aspect, the present invention provides a process of preparing a 3,5-dioxa-12-azawurtzitane compound represented by the following formula (I):
wherein R1 represents an alkyl group, R2 represents a group which, together with a —CH(NH2)COOH group, constitutes an α-amino acid of the formula R2CH(NH2)COOH and which may contain one or more substituents and R3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a polyamino acid, said process comprising reacting an amino acid, an oligo- or polypeptide or a polyamino acid with a trialdehyde represented by the following formula (II): 
wherein R1 has the same meaning as above.
wherein R1 represents an alkyl group, R2 represents a group which, together with a —CH(NH2)COOH group, constitutes an α-amino acid of the formula R2CH(NH2)COOH and which may contain one or more substituents and R3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a polyamino acid, said process comprising reacting an amino acid, an oligo- or polypeptide or a polyamino acid with a trialdehyde represented by the following formula (II):
wherein R1 has the same meaning as above.
In the present specification and claims, the three R1s bonded to the carbon atoms at 1-, 7- and 9-positions of the 3,5-dioxa-12-azawurtzitane compound of the formula (I) or at 1-, 3- and 5-positions of the trialdehyde of the formula (II) may be the same or different alkyl groups.
Other objects, features and advantages of the present invention will be apparent from the detailed description of the preferred embodiments of the invention to follow.
A 3,5-dioxa-12-azawurtzitane compound of the present invention is represented by the above formula (I). In the formula (I), R1 represents an alkyl group preferably having 1-12 carbon atoms. Illustrative of suitable alkyl groups of R1 are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and structural isomers thereof.
The symbol R2 represents a group which, together with a —CH(NH2)COOH group, constitutes an α-amino acid of the formula R2CH(NH2)COOH. Examples of the α-amino acids R2CH(NH2)COOH include glycine (Gly), alanine (Ala), Valine (Val), leucine (Leu), Isoleucine (Ileua), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Try), serine (Ser), threonine (Thre), cystein (CySH), cystine (CyS-SCy), methionine (Meth), aspartic acid (Asp), glutamic acid (Glu), lysine (Lys), arginine (Arg) and histidine (His). The group R2 may contain one or more substituents such as an alkyl group, an acetyl group, an alkoxy group, a benzoxycarbonyl group, a tert-butoxycarbonyl group, a 9-fluorenylmethoxycarbonyl group and a 1,7,9-trialkyl-3,5-dioxa-12H-azawurtzitan-12-yl group.
The symbol R3 represents a hydroxyl group or a group obtained by removing a hydrogen atom of the terminal amino group of an oligo- or polypeptide or a polyamino acid.
Some examples of 3,5-dioxa-12-azawurtzitane compounds of the present invention are shown in Table 1 in which R1, R2 and R3 are the symbols of the formula (I). The 3,5-dioxa-12-azawurtzitane compounds of the present invention, however, are of course not limited to those specifically exemplified compounds. For example, the groups R1, R2 and R3 listed in Table 1 may be arbitrarily selected for any desired combination.
| TABLE 1 | ||||
| R1 | R2 | R3 | ||
| CH3 | H | (His)n | ||
| CH3 | CH3 | (Gly)n | ||
| CH3CH2 | (CH3)2CH | (Ala)n | ||
| CH3CH2CH2 | (CH3)2CHCH2 | (Val)n | ||
| CH3(CH2)3 | CH3CH2(CH3)CH | (Leu)n | ||
| CH3(CH2)4 |
 |
(Phe)n | ||
| CH3(CH2)5 |
 |
(Tyr)n | ||
| H |
 |
(Try)n | ||
| (CH3)2CH | HOCH2 | (Ser)n | ||
| (CH3)2C | CH3(OH)CH | (Thre)n | ||
| (CH3)2CHCH2 | HSCH2 | (CySH)n | ||
| (CH3)2CH(CH2)2 |
 |
(CyS-SCy)n | ||
| (CH3)3C(CH2)3 | CH3SCH2CH2 | (Meth)n | ||
| CH3CH2CH2 | HOOCCH2 | (Asp)n | ||
| CH3(CH2)3 | HOOCCH2CH2 | (Glu)n | ||
| CH3 | H2NCH2(CH2)3 | (Lys)n | ||
| CH3 | HN═C(NH2)NH(CH2)3 | (Arg)n | ||
| CH3 |
 |
OH | ||
In Table 1, n is an integer.
The 3,5-dioxa-12-azawurtzitane compounds of the formula (I) may be prepared by reacting a trialdehyde of the formula (II) with an amino acid, an oligo- or polypeptide or a polyamino acid. The reaction is as follows:
The trialdehyde of the formula (II) may be obtained by any known method such as a method described in Hiroshi IZUMI and Shigeru FUTAMURA, J. Org. Chem. vol. 64, 4502 (1999), the disclosure of which is hereby incorporated by reference herein.
The raw material to be reacted with the trialdehyde of the formula (II) may be expressed by the following formula (III):
(Z)n (III)
wherein Z represents an amino acid and n is an integer of 1 or more with the proviso that, when n is two or more, the amino acids may be the same or different.
(Z)n (III)
wherein Z represents an amino acid and n is an integer of 1 or more with the proviso that, when n is two or more, the amino acids may be the same or different.
Any amino acid may be used as Z of the formula (III). Examples of amino acids include glycine (Gly), alanine (Ala), Valine (Val), leucine (Leu), Isoleucine (Ileu), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Try), serine (Ser), threonine (Thre), cystein (CySH), cystine (CyS-SCy), methionine (Meth), aspartic acid (Asp), glutamic acid (Glu), lysine (Lys), arginine (Arg) and histidine (His). Any oligopeptide (composed of 2 to 9 amino acids), polypeptide (composed of 10 or more amino acids) or polyamino acid (composed of two or more amino acids) may be used as a raw material for the above reaction.
Preferably, the reaction may be performed by mixing an aqueous solution of an amino acid, an oligo- or polypeptide or a polyamino acid with an organic polar solvent solution of the trialdehyde of the formula (II), and reacting the resulting mixture at a temperature and for a period of time sufficient to produce the desired 3,5-dioxa-12-azawurtzitane compound. The trialdehyde is generally used in a stoichiometric amount. The aqueous solution may be a buffer solution. The organic polar solvent may be an aprotic one compatible with water, such as acetone or acetonitrile. The reaction is preferably carried out at 0-70° C. for 0.5-24 hours.
The following examples will further illustrate the present invention.
An acetone solution containing 56 mg of a trialdehyde of the formula (II) was mixed with an aqueous solution containing 51 mg of 3-methyl-L-histidine and the mixture was reacted at room temperature for 2 hours with stirring. The crude product was extracted and purified by chromatography to obtain 90 mg (yield: 94%) of 3,5-dioxa-12-azawurtzitane compound of the formula (I) in which R1 is a methyl group, R2 is a (1-methylimidazol-4-yl)methyl group and R3 is a hydroxyl group. The results of the NMR analysis of the product are shown below.
1H NMR (acetone-d6): δ 0.78 (d, 1H, J=11.9 Hz, methylene H), 0.89 (d, 2H, J=12.1 Hz, methylene H), 0.95 (s, 3H, methyl H), 0.99 (s, 3H, methyl H), 1.01 (s, 3H, methyl H), 1.33 (d, 2H, J=12.1 Hz, methylene H), 1.43 (d, 1H, J=11.9 Hz, methylene H), 3.15 (dd, 1H, J=15.5 Hz, J=9.3 Hz, methylene H), 3.35 (dd, 1H, J=15.5 Hz, J=4.5 Hz, methylene H), 3.65 (s, 3H, imidazole methyl H), 4.24 (dd, 1H, J=9.3 Hz, J=4.5 Hz, methine H), 4.34 (s, 1H, wurtzitane methine H), 4.46 (s, 1H, wurtzitane methine H), 4.74 (s, 1H, wurtzitane methine H), 6.76 (s, 1H, imidazole H), 7.38 (s, 1H, imidazole H).
An acetone solution containing 10 mg of a trialdehyde of the formula (II) was mixed with an aqueous solution containing 14 mg of a peptide Gly-Gly-His and the mixture was reacted at room temperature for 2 hours with stirring. The crude product was extracted and purified by chromatography to obtain 17 mg (yield: 82%) of 3,5-dioxa-12-azawurtzitane compound of the formula (I) in which R1 is a methyl group, R2 is a hydrogen atom and R3 is a Gly-His residue. The results of the NMR analysis of the product are shown below.
1H NMR (acetone-d6/D2O): δ 0.75 (d, 1H, J=12.2 Hz, methylene H), 0.81 (d, 2H, J=11.6 Hz, methylene H), 0.90 (s, 3H, methyl H), 0.94 (s, 3H, methyl H), 0.94 (s, 3H, methyl H), 1.23 (d, 2H, J=11.6 Hz, methylene H), 1.57 (d, 1H, J=12.2 Hz, methylene H), 3.00 (dd, 1H, J=15.3 Hz, J=7.3 Hz, methylene H), 3.16 (dd, 1H, J=15.3 Hz, J=4.9 Hz, methylene H), 3.71 (d, AB, 1H, J=17.1 Hz, methylene H), 3.77 (d, AB, 1H, J=17.1 Hz, methylene H), 3.86 (d, AB, 1H, J=16.9 Hz, methylene H), 3.91 (d, AB, 1H, J=16.9 Hz, methylene H), 4.06 (s, 1H, wurtzitane methine H), 4.08 (s, 1H, wurtzitane methine H), 4.37 (dd, 1H, J=7.3 Hz, J=4.9 Hz, methine H), 4.69 (s, 1H, wurtzitane methine H), 7.16 (s, 1H, imidazole H), 8.41 (s, 1H, imidazole H).
The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all the changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims (3)
1. A 3,5-dioxa-12-azawurtzitane compound represented by the following formula (I):
wherein R3 R1 represents an alkyl group, R2 is selected from the group consisting of hydrogen, the following members:
and said members substituted with one or more of alkyl, acetyl, alkoxy, benzoxycarbonyl, tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, and 1,7,9-trialkyl-3,5-dioxa-12H-azawurtzitan-12-yl, and R3 is selected from the group consisting of hydroxyl, oligopeptides, polypeptides, amino acids and polyamino acids, provided that where R3 is an oligopeptide, polypeptide, amino acid or polyamino acid it is linked through a terminal amino group.
2. A process of preparing a 3,5-dioxa-12-azawurtzitane compound represented by the following formula (I):
wherein R1 represents an alkyl group, R2 is selected from the group consisting of hydrogen, the following members:
and said members substituted with one or more of alkyl, acetyl, alkoxy, benzoxycarbonyl, tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl and 1,7,9-trialkyl-3,5-dioxa-12H-azawurtzitan-12-yl, and R3 is selected from the group consisting of hydroxyl, oligopeptides, polypeptides, amino acids and polyamino acids, provided that where R3 is an oligopeptide, a polypeptide, an amino acid or a polyamino acid, it is linked through a terminal amino group, said process comprising reacting an amino acid, an oligo- or polypeptide or a polyamino acid with a trialdehyde represented by the following formula (II):
wherein R1 R1 has the same meaning as above.
3. A process as claimed in claim 2 , comprising mixing an aqueous solution of said amino acid, an oligo- or polypeptide or a polyamino acid with an organic polar solvent solution of said trialdehyde, and reacting the resulting mixture at a temperature and for a period of time sufficient to obtain said 3,5-dioxa-12-azawurtzitane compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/840,740 USRE39308E1 (en) | 2000-05-09 | 2004-05-07 | 3,5-dioxa-12-azawurtzitane compound and process of preparing same |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000135364A JP3525341B2 (en) | 2000-05-09 | 2000-05-09 | 3,5-dioxa-12-azaurtitanium compounds and methods for producing them |
| JP2000-135364 | 2000-05-09 | ||
| US09/733,063 US6384218B1 (en) | 2000-05-09 | 2000-12-11 | 3,5-dioxa-12-azawurtzitane compound and process of preparing same |
| US10/840,740 USRE39308E1 (en) | 2000-05-09 | 2004-05-07 | 3,5-dioxa-12-azawurtzitane compound and process of preparing same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/733,063 Reissue US6384218B1 (en) | 2000-05-09 | 2000-12-11 | 3,5-dioxa-12-azawurtzitane compound and process of preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE39308E1 true USRE39308E1 (en) | 2006-09-26 |
Family
ID=18643453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/733,063 Ceased US6384218B1 (en) | 2000-05-09 | 2000-12-11 | 3,5-dioxa-12-azawurtzitane compound and process of preparing same |
| US10/840,740 Expired - Fee Related USRE39308E1 (en) | 2000-05-09 | 2004-05-07 | 3,5-dioxa-12-azawurtzitane compound and process of preparing same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/733,063 Ceased US6384218B1 (en) | 2000-05-09 | 2000-12-11 | 3,5-dioxa-12-azawurtzitane compound and process of preparing same |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US6384218B1 (en) |
| EP (1) | EP1153926A3 (en) |
| JP (1) | JP3525341B2 (en) |
-
2000
- 2000-05-09 JP JP2000135364A patent/JP3525341B2/en not_active Expired - Lifetime
- 2000-12-11 US US09/733,063 patent/US6384218B1/en not_active Ceased
- 2000-12-18 EP EP00311328A patent/EP1153926A3/en not_active Withdrawn
-
2004
- 2004-05-07 US US10/840,740 patent/USRE39308E1/en not_active Expired - Fee Related
Non-Patent Citations (9)
| Title |
|---|
| Chem. Commun., 1996, pp. 27-28. * |
| Chemistry Letters, No. 9, 1985, Vpp. 759-760. * |
| Chemistry Letters, No. 9, Vpp. 759-760. |
| J. Chem Soc., Perkin Trans. 1, 1998, 1925-1928, Izumi et al. |
| J. Chem. Soc., Perkin Trans. 1, 1998, 1925-1928, Izumi et al. * |
| J. Org. Chem, 1999, 64, 4502-4505, Izumi et al. * |
| J. Org. Chem., vo. 62, 1997, pp. 1173-1175. * |
| Journal of Organic Chemistry, American Chemical Society, vol. 64, 1999, pp. 4502-4505. * |
| Journal of the Chemical Society, col. 1, 1998, pp. 1925-1928. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001316392A (en) | 2001-11-13 |
| US6384218B1 (en) | 2002-05-07 |
| EP1153926A3 (en) | 2001-11-21 |
| US20020026032A1 (en) | 2002-02-28 |
| EP1153926A2 (en) | 2001-11-14 |
| JP3525341B2 (en) | 2004-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI887230B (en) | Method for producing peptide compound, reagent for forming protecting group, and condensed polycyclic aromatic hydrocarbon compound | |
| TWI866995B (en) | Method for manufacturing peptide compound, reagent for forming protecting group, and condensed polycyclic aromatic hydrocarbon compound | |
| US20220185846A1 (en) | Methods for synthesizing beta-homoamino acids | |
| US12240797B2 (en) | Method of preparing a DON prodrug from L-glutamic acid | |
| USRE39308E1 (en) | 3,5-dioxa-12-azawurtzitane compound and process of preparing same | |
| US20230357311A1 (en) | Method for producing peptide, protective group-forming reagent, and condensed polycyclic compound | |
| CN114667136A (en) | Composition of TROFINETIDE | |
| JP2007534630A (en) | Hydrochloride of glycopeptide phosphonic acid derivative | |
| US20240002432A1 (en) | Method for producing amino acid or peptide, protective group-forming reagent, and compound | |
| CN118382629A (en) | Method for producing peptide compound, reagent for forming protective group and substituted benzyl compound | |
| US11535647B2 (en) | Peptide purification method using sulfonate compound | |
| US6639075B2 (en) | Lactam-aldehyde compound and process of preparing same | |
| IE59987B1 (en) | Process for the n-alpha-trifluoroacetylation of saturated aliphatic monocarboxylic alpha,w-diamino acids | |
| US9126896B2 (en) | Synthesis of diamido gellants by using Dane salts of amino acids | |
| US5506362A (en) | Process for the preparation of an α-amino acid amide | |
| FR2616784A1 (en) | GUANIDINE COMPOUNDS COMPRISING A TETRAPHENYLBORATE ION, PROCESS FOR OBTAINING THESE COMPOUNDS AND USE OF COMPOUNDS DURING PEPTIDE SYNTHESIS | |
| US20110105722A1 (en) | Peptide synthesis method using n-carboxyanhydride (UNCA) | |
| US20240109875A1 (en) | Novel method for synthesizing nca compounds | |
| JP7444363B2 (en) | 2-(2-oxo-4-substituted piperazinyl)cycloalkyl carbamate compound or salt thereof, method for analyzing enantiomers using the compound | |
| US9126897B2 (en) | Synthesis of diamido gellants by using amino acid N-carboxyanhydrides | |
| JP2025037736A (en) | Method for producing N-substituted peptides | |
| US20220185841A1 (en) | Method for producing peptide compound, reagent for forming protective group, and hydrazine derivative | |
| US20030009005A1 (en) | Acetoacetylated diamines and polyamines | |
| US20080281123A1 (en) | Method for Producing Theanine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees |